Displaying drugs 13951 - 13975 of 15156 in total
Metelimumab
Metelimumab (CAT-192) is a monoclonal antibody targeted against transforming growth factor (TGF) beta-1.
Investigational
Certepetide
Investigational
p-Nitrophenylacetic acid
Experimental
N-oxo-2-(phenylsulfonylamino)ethanamide
Experimental
2-(3-NITROPHENYL)ACETIC ACID
Experimental
N-(3-AMINOPROPYL)-2-NITROBENZENAMINE
Experimental
Pumosetrag
Pumosetrag has been used in trials studying Gastroesophageal Reflux Disease.
Investigational
Simfibrate
Experimental
Meptazinol
Experimental
Ty800
Ty800 is a vaccine designed to offer rapid, oral, single-dose protection against Salmonella typhi, the cause of typhoid fever. The Ty800 vaccine was developed using genetic techniques to delete specific genes known to be essential to the virulence of S. typhi. It is being developed by AVANT Immunotherapeutics, Inc.
Investigational
MVA3000
MVA3000 is an attenuated smallpox vaccine that is being developed for use in people for whom the traditional smallpox vaccine is contraindicated, such as patients with disorders of the immune system or skin conditions such as eczema.
Investigational
NUC B1000
NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid delivery system. eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is delivered to...
Investigational
IDD-3
IDD-3 is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. It consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. It includes Dendritophages that are dendritic cells, a type of specialized immune cells derived from the patient's own white blood cells.
Investigational
TA-CIN
TA-CIN is a subunit vaccine comprising L2/E6/E7 proteins from Human Papillomavirus (HPV16), designed to generate a strong cellular immune response against HPV-infected cells.
Investigational
HSV-2 theracine
HSV-2 theracine is an attenuated recombinant vaccine developed by AuRx for the treatment of genital herpes.
Investigational
Q-Derp1
Q-Derp1 is developed by Cytos Biotechnology as an immunodrug. It is an antigen for the prevention of various major chronic diseases. Derp1 is the dominant allergic protein found in dust mite feces.
Investigational
TRX1
TRX1 is a humanized antibody that binds to the CD4 receptor found on a subset of T cells. TRX1 is being developed for the potential treatment of autoimmune diseases in collaboration with Genentech, Inc. TolerRx is currently conducting a Phase I clinical study of TRX1 in the United Kingdom.
Investigational
FAV-201
FAV-201 is a patient-specific immunotherapy for the treatment of T-cell lymphoma.
Investigational
Gavilimomab
Investigational
Displaying drugs 13951 - 13975 of 15156 in total